Kapitalo Investimentos Ltda Makes New Investment in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Kapitalo Investimentos Ltda acquired a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 503 shares of the company’s stock, valued at approximately $66,000.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in shares of Neurocrine Biosciences by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 9,710,328 shares of the company’s stock valued at $1,279,433,000 after purchasing an additional 150,485 shares during the last quarter. Brown Advisory Inc. lifted its position in shares of Neurocrine Biosciences by 2.2% in the 4th quarter. Brown Advisory Inc. now owns 1,113,413 shares of the company’s stock valued at $146,703,000 after acquiring an additional 23,831 shares in the last quarter. Braidwell LP boosted its stake in Neurocrine Biosciences by 3.7% in the 3rd quarter. Braidwell LP now owns 968,024 shares of the company’s stock worth $108,903,000 after purchasing an additional 34,662 shares during the period. Los Angeles Capital Management LLC grew its position in Neurocrine Biosciences by 66.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 918,391 shares of the company’s stock worth $121,007,000 after purchasing an additional 364,986 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new stake in Neurocrine Biosciences during the 4th quarter valued at $105,408,000. 92.59% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Eric Benevich sold 19,818 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now owns 40,778 shares in the company, valued at $5,438,154.08. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, insider Eric Benevich sold 19,818 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $133.36, for a total transaction of $2,642,928.48. Following the completion of the transaction, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Stephen A. Sherwin sold 40,000 shares of Neurocrine Biosciences stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $133.46, for a total value of $5,338,400.00. Following the sale, the director now directly owns 26,504 shares in the company, valued at $3,537,223.84. The disclosure for this sale can be found here. Insiders have sold a total of 88,697 shares of company stock valued at $11,975,615 in the last three months. Company insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $134.07 on Friday. The company has a market capitalization of $13.49 billion, a PE ratio of 36.93 and a beta of 0.36. Neurocrine Biosciences, Inc. has a one year low of $93.02 and a one year high of $148.37. The company’s fifty day moving average price is $137.06 and its 200 day moving average price is $134.92.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. The business had revenue of $515.30 million during the quarter, compared to the consensus estimate of $512.21 million. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.19 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, June 12th. Wedbush reaffirmed an “outperform” rating and set a $152.00 target price on shares of Neurocrine Biosciences in a research note on Wednesday, May 29th. Oppenheimer increased their price target on shares of Neurocrine Biosciences from $200.00 to $216.00 and gave the stock an “outperform” rating in a research report on Thursday, May 2nd. Wells Fargo & Company raised shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $140.00 to $170.00 in a research report on Wednesday, April 24th. Finally, Evercore ISI began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, May 14th. They issued an “outperform” rating and a $175.00 target price for the company. Six investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $152.00.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.